See more : Vertex Corporation (5290.T) Income Statement Analysis – Financial Results
Complete financial analysis of SYBLEU INC (SYBE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SYBLEU INC, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- The Bank of Nova Scotia (BNS) Income Statement Analysis – Financial Results
- Nitin Castings Limited (NITINCAST.BO) Income Statement Analysis – Financial Results
- Rice Acquisition Corp. II (RONI-WT) Income Statement Analysis – Financial Results
- Heineken Holding N.V. (HEIO.VI) Income Statement Analysis – Financial Results
- agilon health, inc. (AGL) Income Statement Analysis – Financial Results
SYBLEU INC (SYBE)
Industry: Biotechnology
Sector: Healthcare
About SYBLEU INC
SYBLEU INC. intends to engage primarily in the development of regenerative medical applications. The company was founded in 2020 and is based in Bronx, New York.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 11.70K | 11.70K | 4.05K | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 11.70K | 11.70K | 4.05K | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 0.00% |
| Research & Development | 85.49K | 5.06K | 29.41K | 39.00K |
| General & Administrative | 75.39K | 63.02K | 62.89K | 7.31K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 75.39K | 63.02K | 62.89K | 7.31K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 160.88K | 68.07K | 92.30K | 46.31K |
| Cost & Expenses | 160.88K | 68.07K | 92.30K | 46.31K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 13.25K | 0.00 | 0.00 |
| Depreciation & Amortization | 7.61K | 175.72K | -7.80K | 46.31K |
| EBITDA | -141.57K | 119.35K | -88.25K | 0.00 |
| EBITDA Ratio | -1,210.42% | 1,020.07% | -2,370.48% | 0.00% |
| Operating Income | -149.18K | -56.37K | -88.25K | -46.31K |
| Operating Income Ratio | -1,275.48% | -481.82% | -2,177.99% | 0.00% |
| Total Other Income/Expenses | -31.12K | -188.97K | 7.80K | 0.00 |
| Income Before Tax | -180.30K | -245.35K | -80.45K | -46.31K |
| Income Before Tax Ratio | -1,541.59% | -2,096.98% | -1,985.49% | 0.00% |
| Income Tax Expense | 0.00 | 13.25K | 21.39K | 0.00 |
| Net Income | -180.30K | -245.35K | -101.85K | -46.31K |
| Net Income Ratio | -1,541.59% | -2,096.98% | -2,513.47% | 0.00% |
| EPS | -0.02 | -0.02 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 10.33M | 10.61M | 10.61M | 9.35M |
| Weighted Avg Shares Out (Dil) | 10.33M | 10.61M | 10.61M | 9.35M |
Goldman Small Cap Research Publishes New Research Report on Sybleu, Inc.
BALTIMORE, MD / ACCESSWIRE / August 24, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on Sybleu, Inc. (OTCPK:SYBE)....
Sybleu Inc. Describes Competitive Landscape Around Artificial Intelligence and Machine Learning in Small Molecule Drug Discovery
NEW YORK , July 18, 2023 /PRNewswire/ -- SYBLEU INC. (OTC PINK: SYBE), a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics, is preparing to begin advancing small molecule drug therapies for animal...
Sybleu Inc. Purchases Fifty Percent Stake In Patent Protected Small Molecule Therapeutic Compounds, Anticipates Synergy With Recently In-Licensed AI/ML Engine
NEW YORK , July 11, 2023 /PRNewswire/ -- SYBLEU INC. (OTC PINK: SYBE), a biotechnology company focused on therapies for human and animal health, medical devices, and clinical diagnostics, is preparing to begin advancing small molecule drug therapies for animal...
Source: https://incomestatements.info
Category: Stock Reports